Global health milestone: WHO adds broad-spectrum sunscreen to Essential Medicines
The World Health Organization’s decision to include broad-spectrum sunscreen with high SPF in the 24th edition of its Model List of Essential Medicines marks a significant step forward for global public health. BASF and Beyond Suncare welcomed this move, underscoring the critical role that accessible sun protection plays in reducing skin cancer risk and protecting communities from harmful ultraviolet (UV) radiation.
Why this listing matters
Sun exposure is a leading environmental risk factor for skin cancer and photoaging. By recognizing broad-spectrum sunscreen as an Essential Medicine, the WHO signals the importance of preventive care that is both practical and scalable in diverse health systems. The decision aligns with broader public health goals to improve equity in access to protective products, particularly in regions with high UV exposure and limited healthcare resources.
Health impact and preventive value
High-SPF, broad-spectrum formulations protect against both UVA and UVB rays, helping to lower incidences of skin cancer and other UV-related conditions. Regular use of effective sunscreen complements other sun-smart behaviors, such as seeking shade and wearing protective clothing. The WHO listing is expected to drive policy discussions, procurement strategies, and educational campaigns that normalize daily sun protection as part of routine health care.
Industry collaboration: BASF and Beyond Suncare’s role
BASF, a global chemical leader with extensive expertise in UV-absorbers and skincare ingredients, and Beyond Suncare, a proactive player in consumer sun protection, emphasized that this WHO recognition validates ongoing investments in research, product safety, and accessibility. Both organizations have been vocal advocates for science-based standards, transparent labeling, and affordability to ensure that more people can benefit from effective sun protection products.
Advancing affordability and access
Access to high-quality sunscreen varies widely by geography and income. The WHO decision is likely to influence national formulary policies, insurance coverage, and subsidy programs, helping to bring essential sun protection within reach for underserved communities. Industry partners say collaborative efforts will be needed to scale production responsibly, maintain quality, and keep costs manageable while meeting rising demand.
Policy implications and next steps
With the Essential Medicines list, policymakers may consider integrating sunscreen into public health campaigns, school-based programs, and workplace wellness initiatives. The next phase involves establishing clear guidance on product standards, age-appropriate formulations, and consumer education to maximize public health impact. Public-private partnerships will be crucial in translating WHO guidance into tangible programs, especially in countries facing heatwaves and high UV index levels.
Looking ahead
As climate conditions evolve and sun exposure becomes an inescapable part of daily life for many communities, the WHO listing provides a solid anchor for preventive health strategies. BASF and Beyond Suncare are prepared to support countries and health systems in implementing effective sunscreen access, ensuring safety, and promoting informed choices for consumers of all ages.
Conclusion
The WHO’s decision to classify broad-spectrum sunscreen with high SPF as an Essential Medicine reinforces the central role of preventive care in public health. By aligning industry innovation with policy objectives, BASF and Beyond Suncare are poised to help expand access to reliable sun protection, ultimately contributing to lower skin cancer risk and healthier communities worldwide.
